Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P2B001 versus individual components and pramipexole ER in early Parkinson's disease
2017-001420-21Phase 3Completed
- Sponsor
- Pharma Two B
- Start
- Feb 2018
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pramipexole + rasagiline, pramipexole and rasagiline in Parkinson's disease (PD) (4 arms), sponsored by Pharma Two B. Primary endpoint: Change in total UPDRS score. Started Feb 2018; status: completed.
02
Drugs
pramipexole + rasagilinepramipexolerasagiline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2017-001420-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001420-21.